Device Trial Radar · NCT06692153
Embecta AID System in Adults With Type 2 Diabetes
Last checked: Nov 19, 2026Latest source record: Dec 16, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Withdrawn
Enrollment
0
Actual
Start
Jan 2025
Primary completion
Mar 2026
Study completion May 2026
Sponsor
- Lead sponsor
- Embecta Corp.Not on our public-company list
- Sponsor type
- Industry
- Collaborators
- Jaeb Center for Health Research
- First posted
- Nov 18, 2024
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multi-center, randomized control study that will evaluate the safety and effectiveness of the embecta Automated Insulin Delivery System in adults with Type 2 diabetes requiring insulin therapy
Conditions
- Type 2 Diabetes
- Type 2 Diabetes Mellitus (T2DM)
- Type 2 DM
- T2DM With Inadequate Glycemic Control
- T2DM (Type 2 Diabetes Mellitus)
- T2D
- T2DM
Interventions
An AID System.Device
The embecta Automated Insulin Delivery (AID) System is a closed loop system comprised of 3 components: the embecta insulin pump, a Smartphone with the Tidepool Loop app, and the Dexcom G6 CGM
Standard of Care (SC)Other
Participants will continue to use their current therapy for T2D.
Primary outcomes
What the sponsor says the trial is designed to measure.
- HbA1c changeTime frame: 13 weeks
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
Stanford
Palo Alto, California
Diablo Research
Walnut Creek, California
Indiana Universtiy School of Medicine
Indianapolis, Indiana
6 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.